JOURNAL OF BONE AND MINERAL METABOLISM, published by SPRINGER JAPAN KK, is a leading peer-reviewed journal dedicated to advancing the field of bone and mineral research since its establishment in 1988. With ISSN 0914-8779 and E-ISSN 1435-5604, this esteemed journal offers a platform for high-quality research that intersects Endocrinology, Diabetes and Metabolism, Orthopedics and Sports Medicine, and related disciplines. Recognized for its rigorous standards, it holds a commendable Q2 ranking in multiple categories, reflecting its broad influence and relevance in contemporary medical research. Researchers and practitioners alike benefit from its evidence-based articles and insights, which contribute significantly to our understanding of metabolic bone diseases and mineral homeostasis. Although not an open-access journal, it still provides essential information and advancements crucial for professionals and scholars dedicated to improving clinical outcomes and enhancing patient care in these vital areas. To learn more, please explore the journal's archives and latest publications.

PROSTATE is a premier, peer-reviewed journal published by Wiley, focusing on the critical fields of urology and oncology. With an established history since 1980 and a projected convergence through 2024, this influential journal serves as a vital resource for researchers, clinicians, and students alike. It holds a prestigious position in the academic landscape, classified in the Q1 category for Urology and Q2 in Oncology as of 2023, demonstrating its significant contribution to these disciplines. With a Scopus rank of #23 in Urology and #169 in Oncology, PROSTATE is pivotal for advancing knowledge and fostering innovation in prostate research, treatment, and overall male health. The journal aims to publish high-quality original articles, reviews, and clinical studies that address the complexities of prostate-related conditions, ultimately seeking to improve patient outcomes and propagate best practices in the medical community.

JOMR-Journal of Oral & Maxillofacial Research is a leading open-access journal dedicated to the dissemination of high-quality research in the field of oral and maxillofacial sciences. Published by UAB Stilus Optimus, this journal has been a vital resource for researchers, clinicians, and educators since its inception in 2010, promoting innovative findings and insights that advance our understanding of oral health and surgical procedures. With an ISSN of 2029-283X, JOMR publishes a diverse range of articles covering clinical studies, case reports, and reviews, establishing itself as an essential platform for sharing knowledge among professionals in dentistry and maxillofacial surgery. The journal's commitment to open access ensures that its cutting-edge research is freely available to a global audience, enhancing collaboration and fostering academic dialogue within the field. As an important contributor to the scholarly community, JOMR plays a crucial role in shaping future research and practice in oral and maxillofacial care.

Journal of Cancer is a premier, peer-reviewed academic journal published by IVYSPRING INTERNATIONAL PUBLISHING that focuses on advancing the field of oncology. With an impact factor reflecting its significant contributions, this journal ranks in the 80th percentile of medical journals pertaining to oncology, positioning it at #79 out of 404 in Scopus. Since its inception in 2010, the journal has embraced an Open Access model, ensuring that groundbreaking research reaches a global audience without barriers. Based in Australia, the journal addresses a wide array of topics within cancer research, catering to researchers, healthcare professionals, and students committed to enhancing their understanding of the complexities of cancer. Amidst evolving challenges in oncology, the Journal of Cancer serves as a vital platform for disseminating innovative findings, fostering collaboration, and promoting informed decisions that can lead to improved cancer outcomes worldwide.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, published by Springer, is a prestigious peer-reviewed journal dedicated to advancing the fields of cancer research and clinical oncology. With an impact factor reflecting its significance within the academic community, the journal operates under a rigorous quality standard and offers a wealth of knowledge spanning from 1979 and continuing through 2025. With its comprehensive scope, it encompasses a wide array of topics including novel therapeutic strategies, clinical trials, and cutting-edge research methodologies, making it an essential resource for researchers, practitioners, and students alike. The journal’s category quartiles highlight its competitive edge, ranking Q2 in Cancer Research and Q1 in Medicine (miscellaneous) as of 2023. This positioning underscores its role at the forefront of oncology discourse. Through this journal, contributors and readers alike engage with impactful research that informs clinical practices and enhances patient care in oncology. Access to the journal’s content, although not open access, ensures curated and high-quality insights available to the academic and professional community.

Cancer Research Communications is an esteemed journal published by the American Association for Cancer Research, a leading organization in the field of oncology. This journal aims to advance knowledge in cancer research through the dissemination of high-quality, peer-reviewed articles that cover a wide range of topics related to cancer biology, treatment modalities, and prevention strategies. As an open-access journal, Cancer Research Communications ensures that vital research findings are accessible to a global audience, promoting collaboration and innovation within the scientific community. The journal serves as a crucial platform for researchers, professionals, and students to share their insights and foster the exchange of effective cancer therapies and methodologies. With a commitment to excellence, it plays a significant role in shaping the future of cancer research and therapeutic development.

Chinese Journal of Cancer Research, published by Chinese Journal Cancer Research Co, is a pivotal platform for disseminating significant findings in the field of oncology. Since its inception in 1988, the journal has provided a comprehensive forum for cancer research, featuring peer-reviewed articles that cover various aspects of cancer biology, prevention, diagnosis, and treatment. Although the journal's coverage is currently discontinued in Scopus and holds an HIndex that has not been specified, it is ranked in the 65th percentile in Medicine - Oncology and the 48th percentile in Biochemistry, Genetics and Molecular Biology - Cancer Research. This reflects its commitment to maintaining quality and relevance in the rapidly evolving field of cancer research. Researchers, professionals, and students are encouraged to explore its rich archive of studies and breakthroughs to enhance their understanding and further their research. For access, the publication remains instrumental for those invested in advancing the global fight against cancer.

The Journal of Cancer Research and Therapeutics is a prominent peer-reviewed platform dedicated to advancing scientific knowledge in the fields of oncology, radiology, and therapeutic interventions. Published by Wolters Kluwer Medknow Publications in India, this journal has been an essential resource for researchers and professionals since its inception in 2005, with a convergence of findings through to 2024. Although classified within the Q3 quartile across multiple relevant categories in the 2023 rankings, the journal maintains a significant impact in the fields of medicine, particularly in oncology and radiology, as evidenced by its Scopus rankings. The journal aims to disseminate high-quality research, case studies, and clinical trials that contribute to understanding and improving cancer treatments and patient care. With its accessibility to a global audience, the Journal of Cancer Research and Therapeutics plays a pivotal role in fostering dialogue and collaboration among researchers and healthcare professionals dedicated to combating cancer.

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

BONE, published by Elsevier Science Inc, is a leading peer-reviewed journal that has established itself as a pivotal resource in the fields of Endocrinology, Diabetes and Metabolism, Histology, and Physiology. Since its inception in 1985 and continuing to 2025, this journal has consistently provided high-quality research, evidenced by its impressive Q1 category rankings and strong performance in Scopus metrics—ranking #7 in Histology and achieving notable percentiles in related fields. With a commitment to advancing knowledge and understanding in bone biology and associated pathological conditions, BONE serves as an essential platform for researchers and professionals aiming to contribute to the discourse in skeletal health and disease. While it is not an open-access publication, the journal ensures a broad dissemination of pivotal research findings, making it a critical asset for academics and practitioners devoted to fostering advancements in medical sciences.